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Background: The Src homology and collagen A (ShcA) adaptor protein plays a crucial role in heart development but the
underlying mechanisms are unknown.
Results: Early conditional deletion of ShcA in cardiomyocytes leads to heart failurewith abnormalities in the costamere/Z-disk network.
Conclusion: ShcA protects against heart failure by maintaining costameres/Z-disk axis integrity.
Significance: Understanding molecular mechanisms involved in heart failure may help to develop new therapies.
Src homology and collagen A (ShcA) is an adaptor protein
that binds to tyrosine kinase receptors. Its germ line deletion is
embryonic lethal with abnormal cardiovascular system forma-
tion, and its role in cardiovascular development is unknown. To
investigate its functional role in cardiovascular development in
mice, ShcA was deleted in cardiomyocytes and vascular smooth
muscle cells by crossing ShcA flox mice with SM22a-Cre trans-
genic mice. Conditional mutant mice developed signs of severe
dilated cardiomyopathy,myocardial infarctions, and premature
death. No evidence of a vascular contribution to the phenotype
was observed. Histological analysis of the heart revealed aber-
rant sarcomeric Z-disk and M-band structures, and misalign-
ments of T-tubules with Z-disks. We find that not only the
ErbB3/Neuregulin signaling pathway but also the baroreceptor
reflex response, which have been functionally associated, are
altered in the mutant mice. We further demonstrate that ShcA
interacts with Caveolin-1 and the costameric protein plasma
membrane Ca2/calmodulin-dependent ATPase (PMCA), and
that its deletion leads to abnormal dystrophin signaling. Collec-
tively, these results demonstrate that ShcA interactswith crucial
proteins and pathways that link Z-disk and costamere.
Heart failure is defined as the inability of the heart to suffi-
ciently pumpblood tomeet themetabolic demands of the body.
It is a progressive and complex pathology usually accompanied
by dilated cardiomyopathy. Signaling through Z-disk-associ-
ated proteins (1, 2) or pathways involving tyrosine kinase recep-
tors such as ErbB2 receptors in the cardiac T-tubule system are
among the mechanisms that cause dilated cardiomyopathies
(3, 4).
ShcA5 is an ubiquitously expressed adaptor protein that
binds specific phosphotyrosine (Tyr(P)) sites of tyrosine kinase
receptors, such as the platelet-derived growth factor receptor,
the insulin-like growth factor receptor, or ErbBs once activated
by phosphorylation (5). ShcA also binds to integrins (6). ShcA
recruitment to the plasma membrane causes its phosphoryla-
tion on tyrosine residues, which, in turn, induces the formation
of a stable complex with the adaptor protein Grb2 and the Ras
guanine nucleotide exchange factor SOS (5, 7). These events
lead to the activation of the Erk/mitogen-activated protein
kinase pathway and cell proliferation (5, 8). Germline deletion
of ShcA in mice leads to profound embryonic cardiovascular
defects (9), whereas deletion of ShcA in cardiomyocytes after
birth induces a moderately impaired systolic function (10).
Thus, ShcA plays a crucial role during heart development, but
the underlying molecular mechanisms are largely unknown.
Costameres are platforms in the plasmamembrane that par-
ticipate in signaling between the extracellular matrix and the
Z-disk. Costameres encircle the myocyte perpendicular to its
long axis, and are comprised of two protein complexes: the
dystrophin-glycoprotein complex (DGC) and the vinculin-
talin-integrin system, where ShcA localizes through its interac-
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tion with integrins. The DGC consists of dystrophin, sarcogly-
cans, dystroglycans, syntrophins, and sarcospan in the costameres
of muscle cells (2). Caveolin-1 (Cav-1) and Caveolin-3 (Cav-3)
are the predominant caveolin isoforms in the heart, and are also
part of the DGC. Only Cav-1 is required for caveolae formation
and has been described to functionally interact with ShcA (11),
but both Cav-1 and Cav-3 have been identified as potential
regulators of heart disease (12). The cardiomyocyte plasma
membraneCa2-ATPase (PMCA) that extrudes Ca2 from the
cytosol (13) binds to -syntrophin and NOS-1 in cardiac cells
(14), and is thus a part of the dystrophin complex. Interestingly,
ShcA induces apoptosis through down-regulation of PMCA,
suggesting a functional interaction between ShcA and PMCA
(15). Furthermore, PMCA binds to PDZ domain-containing
proteins through its C terminus (16) and directly associates
with the tumor suppressor Ras-associated factor (RASSF1) to
inhibit the Ras/Erk pathway (17), the downstream effector of
ShcA. Thus, by functionally interacting with ShcA, PMCA
could be a hub for ShcA/Cav-1 and -syntrophin/NOS-1 in the
DGC.
Because the genetic deletion of ShcA in adult mice leads to a
moderate cardiac phenotype (10), we reasoned that its deletion
in cardiomyocytes during early embryogenesis could lead to
structural changes and signaling alterations that may help to
understand its role during mouse heart embryonic develop-
ment. We sought to evaluate this relationship using Cre-loxP
technology and the Sm22cre transgene, because Sm22 is
already expressed at E8.5 in the heart andwill remain expressed
in the cardiovascular system throughout adulthood (18, 19).
The resulting phenotype was a severe dilated cardiomyopathy
with aberrant intercalated disk structures and sudden death
after birth. Our data suggest that loss of ShcA activity in the
heart leads to abnormal ErbB3 and dystrophin signaling in the
costamere/Z-disk axis and provide insight into the molecular
mechanisms by which ShcA regulates heart development and
function.
EXPERIMENTAL PROCEDURES
Animals and Diets—All animal experimentation and proce-
dures were approved by the Institutional Animal Care and Use
Committee (IACUC) of the University of Strasbourg, France.
We generated mice with loss of ShcA in cardiovascular tissue,
using LoxP-flanked ShcA alleles and the Sm22Cre recombinase
transgene (Sm22cre) (20). The 10.1-kbDNA sequence contain-
ing the mouse exon 1 to exon 11 segments of ShcA, two loxP
sites (flanking exons 2 to 7), and a PKG neomycin resistance
cassette flanked by two FRT sites, were cloned into the pBlue-
Script SK() vector (targeting vector). The PKG neomycin
resistance cassette was excised by crossing ShcA flox/FRTmice
with mice expressing flippase recombinase. The resulting
Sm22Cre; ShcAflox/flox mice in which ShcA was ablated in
heart are referred to as smShcA, and their age and sex-
matched control littermates are referred to as Ctrl (Sm22Cre;
ShcAflox/flox). In the smShcA animals, the deleted genomic
sequence contains exons 2 to 7, which encodesmost of the PTB
domain of the ShcAprotein.Genotyping of thewild-type floxed
andnull alleles of ShcAbypolymerase chain reaction (PCR)was
performed as described (20) using primers specific for ShcA
(primers available upon request). For atherogenic studies,
mutants and controlmice were fed a Paigen diet for 24weeks as
described previously (20).
Echocardiography, Blood Pressure Measurements, and Elec-
tronMicroscopy—Animals were weighted and analyzed for car-
diac anatomy and function on a Sonos 5500 (Hewlett Packard)
with a 15 MHz linear transducer (15L6). Mice were anesthe-
tized with isoflurane (2% in O2), placed on a heating table, and
the chest area was depilated. The measurements were per-
formed as previously described (21). The heart was first imaged
in the two-dimensional mode in the parasternal long-axis view
to obtain the aortic root dimensions. The aortic flow velocity
and the heart rate were measured with a pulsed-wave Doppler
on the same section. The sample volume cursor was placed in
the aortic root and the transducer was angled slightly, which
allowed paralleling the aortic flow with the interrogation beam
so that the maximum aortic flow velocity was obtained easily.
The cardiac output was calculated from the following equation:
cardiac output 0.785D2VTI heart rate, whereD is the
internal diameter of the aortic root andVTI is the velocity-time
integral of the Doppler aortic spectrum. Left ventricular cross-
sectional internal diameters in end-diastole (LVEDD) and in
end-systole (LVESD)were obtained by anM-mode analysis of a
two-dimensional short axis view at the papillary muscle level.
The shortening fraction was calculated as SF  (LVEDD-
LVESD/LVEDD)  100, and the ejection fraction using the
equation: ejection fraction (LVEDV-LVESV/LVEDV) 100,
where LVEDV and LVESV are, respectively, LV end-diastolic
and LV end-systolic volumes. From this view, the diastolic sep-
tum (S) and posterior wall thicknesses were measured. The left
ventricular mass was calculated as described (22, 23). All mea-
surements were performed on at least three beats, according to
the guidelines of the American Society of Echography. Frac-
tional shortening and ejection fraction were calculated accord-
ing to the Teichholz formula (24).
Systolic blood pressure rate was recorded by the tail-cuff
method in awake mice (Letica model 5002). Electron micros-
copy was performed as described (25).
In Vivo Myocardial Perfusion Measurement Using MRI—In
vivo magnetic resonance images were acquired using a Bruker
Biospec 4.7T/30 imager (Bruker Biospin, Ettlingen, Germany).
During the MRI protocol, animals were anesthetized with 1.2–
1.6% isoflurane delivered in a 0.6 ml/min oxygen gas stream
through a dedicated nose cone. An ECG- and respiration-gated
Lock-Locker Gradient Echo Flow-sensitive Alternating Inver-
sion Recovery Arterial Spin Labeling technique setup and vali-
dated earlier (26, 27) was used to acquiremyocardial blood flow
(MBF)maps from a single short-axis slice placed at left ventric-
ular (LV)midlevel. The following parameterswere used: field of
view 25  25 mm2, spatial resolution 195  390 mm2, slice
thickness 1.5 mm. The total MBF acquisition time was 25
min. Perfusion raw images were post-processed as described
earlier (26, 27). GlobalMBFwas determined bymanually delin-
eating regions of interests in the anterior half of the mid-LV
myocardium on the corresponding MBF maps.
Vascular Reactivity—Thoracic aortas were carefully removed
and mounted on a multiwire myograph system (Danish Myo
Technology) filled with physiological salt solution (PSS) under
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normalized tension as previously described (28). Vessels were
contracted by cumulative addition of increasing concentrations
of phenylephrine in the organ bath. Contractions were expressed in
millinewton/mm aortic ring length.
Cell Culture—H9C2 rat cardiac myoblasts were purchased
from the ATCC and grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum and 1.5
g/liter of sodium bicarbonate.
Immunoprecipitation—Heart or H9C2 cells were washed
with ice-cold PBS and lysed for 20 min on ice in lysis buffer
supplemented with protease and phosphatase inhibitors as
described (20). Protein was immunoprecipitated from lysates
with anti-PMCA or anti-ShcA or nonimmune IgG and protein
A/GPlus-agarose (SantaCruz Biotechnology) as described pre-
viously (20). Precipitated proteins were separated by SDS-gel
electrophoresis and immunoblotted with antibodies against
PMCA, ShcA, and caveolin-1.
IsolationofMousePeritonealMacrophages—Ctrl andsmShcA
mice were injected intraperitoneally with 1ml of 3% thioglycol-
late (Sigma) and peritoneal lavage was harvested 3 days later.
These cells were tested for CD68 and galectin-3 expression by
Western blot.
siRNA Transfections—H9C2 cells were plated and treated
with siGENOME Smart Pool Shc1 siRNA according to the
Dharmacon protocol. Cells were collected 3 days latter for pro-
tein analysis.
Confocal Microscopy—Cardiomyocytes isolated from con-
trol and smShcA mice, and H9C2 cells were seeded on glass
slides, fixed with paraformaldehyde, and incubated with anti-
PMCA and anti-caveolin-1 or anti-IgG control primary anti-
bodies and Alexa Fluor 488 and Alexa Fluor 546 secondary
antibodies. Immunofluorescence-labeled cells were analyzed
using a Leica TSC SPE confocal microscope with the 63 oil
immersion objective.
Protein and mRNA Expression Analysis—RNA was isolated
using TRIzol reagent (Sigma) according to the manufacturer’s
instructions. 50 ng of RNA were converted to cDNA using the
High-capacity cDNA Archive kit (Applied Biosystems, Foster
City, CA). PCR amplificationwas performed using SYBRGreen
PCR master mixture (Applied Biosystems) according to the
manufacturer’s instructions. Primer sequences are available
upon request. SDS-polyacrylamide gel electrophoresis and
immunoblot analysis were performed according to standard
procedures. Proteins were transferred onto nitrocellulose
membranes and immunoblot analyses were carried out using
antibodies directed against ShcA (Upstate), Cav-1 (SantaCruz),
Cav-3 (Santa Cruz), CD68 (Santa Cruz), dystrophin (Abcam,
Cambridge,MA), galectin-3 (Abcam), paxillin (Santa Cruz), 7
(Santa Cruz), p44/42 Erk (Cell Signaling Technology), p-AKT
(Cell SignalingTechnology), P-mammalian target of rapamycin
(Cell Signaling Technology), PMCA (Santa Cruz), or GAPDH
(Sigma). Titin protein levels were quantified by vertical-agarose
gel electrophoresis following the published protocol (29).
Briefly, protein samples were prepared by homogenization of
the LV in liquid N2 and lysis in 8 M urea, 50% (v/v) glycerol,
DTT (80 mM final)/protease inhibitors (Roche Applied Sci-
ence). Titin isoforms were separated by SDS-agarose gel elec-
trophoresis followed by Coomassie Blue staining. AIDA soft-
ware (Raytest) was used to quantify titin and myosin heavy
chain (MHC) and GraphPad Prism (GraphPad Software, Inc.)
for statistical analysis. For the titin domain phosphorylation
assay, His6-tagged Zis1 and Zis5 were amplified from mice
heart cDNA by PCR using primer pairs: Zis1F (5-TCCACTG-
CAGAATTGGTGGTTCAAG-3), Zis1R (5-GTAGAGCTT-
GTCATTGTCGTCTCTC-3), Zis5F (5-CATTGCAAGATG-
TCTGGATAT-3), and Zis5R (5-CAGTGACTGAGTTCCA-
TCTTC-3). The obtained fragments were subcloned into the
pASK-IBA3 expression vector. His6-tagged titin domains were
purified and phosphorylation assays were done as previously
described (30). Briefly, cell extracts from cardiac tissues of adult
mice and embryos were added to phosphorylation assays buffer
(25 mMHepes, pH 7.2, 10 mMMgCl2, 1 mM EGTA, 1 mMDTT,
0.2 mM ATP, and 1 mCi of [-33P]ATP, 3,000 Ci/mM) at 37 °C
for 10 min. The reactions were stopped by heating samples at
95 °C for 1 min and analyzed on 18% polyacrylamide gels. Gels
were dried and autoradiographed with intensifying screens at
80 °C for 12 to 24 h.
Immunostaining Analysis—For immunostaining and histol-
ogy experiments, hearts were cut longitudinally at the midven-
tricular level, fixed with 4% paraformaldehyde in phosphate-
buffered saline, embedded in paraffin, and cut in 5-m slices as
described (20). Sections were stained with eosin and hematox-
ylin for images of chamber cross-sections or with Sirius red to
evaluate the degree of left ventricular interstitial fibrosis.
Statistical Analysis—Values are reported asmean S.E. of at
least triplicate determinations. Statistical significance (p 	
0.05) was determined using an unpaired Student’s t test
(GraphPad Prism, Abacus Concepts, Berkeley, CA).
RESULTS
Conditional ShcA Mutants Develop a Severe Cardiac Dys-
function and Die Prematurely—In offspring from matings
between smShcA (Sm22Cre, ShcAflox/flox) and control mice
(Sm22Cre, ShcAflox/flox) the three ShcA isoforms were effi-
ciently reduced in the heart during embryogenesis (E14.5,
E18.5) and in the adults (Fig. 1A). Animals were born following
the expected Mendelian ratios, but about 5% of conditional
mutantmice died prematurely (Fig. 1B). Deathwas sudden sug-
gesting an acute event, whereas no changewas observed in body
weight (26.2  0.65 g in 3-month-old mutants, versus 27.6 
0.71 g in controls, not significant). Surviving smShcA mice
exhibited leg edema (Fig. 1C), a frequent sign of heart failure. In
surviving smShcAmice, hearts were enlarged with dilation of
the left ventricle (Fig. 1D). Heart diameter and function in
adults were followed by echocardiography. Compared with
controls, left ventricle weight was increased in mutant mice
(136  13 mg in mutants, versus 102  6 mg in controls, p 	
0.05) at 3 months of age (Table 1). Left ventricle to body weight
ratios of adult conditional mutants calculated from echocar-
diographywere also increased relative to controls by 30% (5.2
0.4 mg/g in mutants, versus 3.7  0.1 mg/g in controls, p 	
0.01), a further indication of cardiac hypertrophy (Table 1). The
average left ventricular end-systolic (4.6 0.4 mm in mutants,
versus 2.9  0.1 mm in controls, p 	 0.001) and end-diastolic
diameters (5.4  0.3 mm in mutants, versus 4.4  0.1 mm in
controls, p	 0.01) were substantially increased inmutant mice
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(Fig. 1, E and F, and Table 1). Fractional shortening (17 2% in
mutants, versus 35  2% in controls, p 	 0.001), a measure of
cardiac output (Fig. 1G) and ejection fraction (40  4% in
mutants, versus 71 3% in controls, p	 0.001) were all mark-
edly impaired in smShcA mice (Table 1). Echocardiography
also revealed frequent arrhythmias and loss of contractility in
large territories of smShcA hearts (supplemental Videos S1
and S2). A moderate but significant increase in systolic blood
pressure (Fig. 1H) with no change in heart rate (Table 1) was
observed in adult smShcA mice. Pulmonary hypertension,
which is an additional sign of heart failure, was also observed in
several mice during echocardiography through the observation
of an enlarged right ventricle. Moreover, ECG examination
showed a T-wave inversion caused by slowed ventricular repo-
larization in the mutant compared with controls, whereas in
vivo noninvasive quantitative myocardial perfusion mapping
using magnetic resonance images (MRI) showed normal coro-
nary perfusion inmutantmice (Fig. 2A) with no change inmyo-
cardial blood flow (5.8 0.4 ml/g/min in mutants, versus 6.5
0.5 ml/g/min in controls, not significant). Defects are present
before birth. With aging, cardiac function did not decline fur-
ther. Fractional shortening (17.1 2.2% at 3months old, versus
16.0 0.5% at 9 months old, not significant) and ejection frac-
tion (41.5  4.6% at 3 months old, versus 38.2  0.8% at 9
months old, not significant) remained unchanged at 3 months
compared with 9-month-old smShcAmice.
Histological analysis of adult conditional mutant and control
mice revealed enlarged ventricular chambers in smShcA ani-
mals, abnormal tissue organization and morphology, and dis-
FIGURE 1. Reduced survival and left ventricular dysfunction in smShcA adult mice. A, Western blot analysis of ShcA in embryonic hearts at E14.5, E18.5,
and in hearts from 3-month-old smShcA and control mice (Ctrl). B, Kaplan Meier curves showing reduced survival of smShcAmice compared with control
littermates (Ctrl) from birth (1 day) to 10months old. C, representative image of leg edema (arrow) in 6-month-old smShcAmice.D, gross anatomy of cardiac
enlargement in 6-month-old mutant mice and littermate controls. E, echocardiographic cardiac output measurements in 3-month-old mutant and control
mice. F, echocardiographic images (axial and M-mode) showing the anterior (a) and posterior (p) wall thickness as well as the increase in the LVEDD, and the
LVESD in representative3-month-old smShcAmice (bottom) and littermate controls (top).G, quantificationof cardiacoutput in3-month-oldmutantmiceand
littermate controls. H, increased systolic blood pressure in 3-month-old mutant mice (smShcA) compared with controls (Ctrl). For panels G and H, values are
mean S.E. with *, p	 0.05 compared with littermate controls. n 10 per group.
TABLE 1
Echocardiographic parameters
Echocardiography of smShcAmice and controls.
Controls
S.E.
smShcAa
S.E. p
LVb weight (mg) 102 6 136 13 	0.05
LV weight/total weight (mg/g) 3.7 0.1 5.2 0.4 	0.01
LVEDD (mm) 4.4 0.1 5.4 0.3 	0.01
LVESD (mm) 2.9 0.1 4.6 0.4 	0.001
Fractional shortening (%) 35 2 17 2 	0.001
Ejection fraction (%) 71 3 40 4 	0.001
Heart rate (beats/min) 421 7 428 17 NSc
Aortic root diameter (mm) 0.15 0.01 0.16 0.01 NS
a smShcA, cardiovascular-specific ShcA knockout mice (n
 6 per group).
b LV, left ventricle.
cNS, not significant.
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ruption of myofibrils (Fig. 2B). Histological evidence of myo-
cardial infarction, such as necrotic areas, were observed as early
as embryonic day E18.5 (Fig. 2C). Masson’s trichrome and Sir-
ius red staining did not reveal any increase in myocardial inter-
stitial fibrosis in smShcAmice compared with controls (data
not shown).
Effects of ShcA Deficiency Are Largely Compensated in the
Vasculature—The Sm22 protein is expressed in both vascular
and visceral smooth muscle cells and more recently it was
detected in myeloid cells (31). We examined the expression of
ShcA in visceral smooth muscle cell-containing tissues such as
intestine, bladder, lung, muscle, spleen, and macrophages (31),
and found no difference in smShcAmice compared with con-
trols (Fig. 3A). Thus, it is unlikely that these tissues contributed
to the observed phenotype. Because in vascular smooth muscle
cells ShcA levels are strongly decreased (Fig. 3A), we evaluated
the vascular contribution to the observed cardiac phenotype.
Histological analysis of H/E-stained aorta showed no signifi-
cant difference in tissue organization andmorphology (Fig. 3B,
left panel). Also no difference in tissue organization was
observed in electron microscopy (Fig. 3B, right panel). Simi-
larly, there was no difference in aortic root diameter in
smShcA compared with control mice (Table 1). We further
tested whether the moderate increase in blood pressure could
be explained by an altered vascular reactivity. In aortas from
smShcA versus control animals there was no significant dif-
ference in the vasoconstrictive response upon phenylephrine
treatment (Fig. 3C). However, this does not rule out a potential
contribution of altered microvascular reactivity to the hyper-
tensive state. Vascular smooth muscle cells are known to play a
role in the development of atherosclerotic lesions, and ShcA is
able to bind to the cytoplasmic tail of LRP1, a transmembrane
receptor known to protect against atherosclerosis when
expressed in vascular smooth muscle cells (20). As atheroscle-
rosis is a risk factor frequently associated with cardiovascular
disease in humans, we assessed if atheroprone conditions
would worsen the cardiac phenotype of smShcA mice.
Accordingly, we bred the mice on a LDL receptor deficiency
background to increase their susceptibility for atherosclerosis,
fed them an atherogenic diet, and analyzed the atherosclerotic
phenotype. In contrast to LRP1-deficientmice, Sm22cre-medi-
FIGURE 2. Cardiac necrosis in the absence of ShcA. A, color-coded cardiac perfusion (MBF) maps representative for each group of 3-month-old animals. B,
H&E-stained sagittal (top) and axial (bottom) sections from3-month-old smShcAmice hearts and littermate controls. Thewhite arrow shows disruption of the
tissue. Scale bars, top panels 3mm; bottompanels 200m.C, toluidine blue staining showsnecrotic regions in the heart from smShcAmice and controls
at E18.5 (white arrow andwhite square). Scale bars, top panels 500 m; bottom panels 200 m.
Organization of the Heart Costamere/Z-disk Network by ShcA
JANUARY 23, 2015•VOLUME 290•NUMBER 4 JOURNAL OF BIOLOGICAL CHEMISTRY 2423
ated ablation of ShcA did not lead to an increase in atheroscle-
rotic lesions, even when mice were bred on a background of
LDLr deficiency and fed an atherogenic diet, as demonstrated
by sizemeasurements of lesions (Fig. 3D), and en face analysis of
the aortic lesion area (Fig. 3E). Furthermore, under these
atheroprone conditions, echocardiographic parameters did not
worsen (data not shown). Thus, we did not find any obvious
abnormalities in the vascular systemof ShcAmutantmice. This
suggests that there is no vascular contribution to the cardiac
phenotype in ShcA-deficient mice.
Abnormal ErbB3 Signaling in the Hearts of Conditional
Mutant Mice—We next evaluated the molecular basis of the
dilated cardiomyopathy phenotype in the absence of ShcA.
Because the heart has achieved its definitive configuration by
E15.5 (except for the atrioventricular valve leaflets and coro-
nary artery) (32), we analyzed embryos between E14.5 and
E18.5. Although ShcA has been reported to be critical for
MAPK activation or the switch from AKT/mammalian target
of rapamycin toward Erk activation (33), there were no signifi-
cant changes in phospho-Erk, phospho-AKT, or phospho-
mammalian target of rapamycin indicative of Erk or AKT acti-
vation, in heart lysates from E14.5, E18.5, or 3-month-old
mutant mice compared with controls (data not shown). How-
ever, we observed marked disruption of myofibrillar architec-
ture and mitochondrial hyperplasia, which were already pres-
ent at E14.5 in mutant cardiomyocytes, as revealed by electron
microscopy (Fig. 4A). At E18.5, we found myofibrillar disarray
(Fig. 4A). This includes severe changes in the Z-disk and
M-band of the sarcomere. Z-disks link myofilaments to mem-
brane systems, specifically to the T-tubules (34, 35), and trans-
mit biomechanical stress through associated signaling proteins
(36). In smShcA mutants at E18.5 as sarcomeres matured, we
observed Z-disk thickening (Fig. 4, A and B), as well as loss of
defined M-band structures (Fig. 4A). Morphology was abnor-
mal, with bubbling and misalignment of T-tubules with Z-disk
components (Fig. 4A). To link ShcA to Z-disk- and T-tubules-
associated abnormalities, we studied the ErbB receptor tyrosine
kinase pathway, which is important for T-tubule integrity and
protects against dilated cardiomyopathy (3, 4). Furthermore,
the PTB domain of ShcA interacts with tyrosine kinase recep-
tors including ErbB (5). We found that protein levels of the
ErbB3 receptor were significantly decreased at E14.5 in
mutants compared with controls (0.55 0.04 in mutants, ver-
sus 0.75  0.04 in controls, p 	 0.05) (Fig. 4C). No significant
change was found at E18.5 (0.59  0.04 in mutants, versus
0.62 0.02 in controls, not significant) (Fig. 4C). ErbB3 recep-
tor protein expression levels were almost undetectable in adult
mice (data not shown), however, ErbB3 receptor mRNA levels
were decreased in adult mutants compared with controls (Fig.
4D). There was no difference in the relative mRNA levels of
ErbB2 (0.98 0.52 in mutants, versus 1 in controls, not signif-
icant) and ErbB4 receptors (1.04 0.25 in mutants, versus 1 in
controls, not significant) comparedwith controls. In agreement
with an altered ErbB3 signaling in the absence of ShcA, we
found in mutants at E18.5, a decrease in protein levels of both
p26 (0.58 0.04 inmutants, versus 0.75 0.04 in controls, p	
0.01) and p30 (0.45  0.04 in mutants, versus 0.62  0.02 in
controls, p	 0.01) active isoforms of Neuregulin-1 (Nrg-1), the
ligand of the ErbB receptors (37). The p45 isoform remained
unchanged (0.11 0.01 in mutants, versus 0.16 0.02 in con-
trols, not significant). At E14.5, the protein levels of p26 (0.87
0.13 in mutants, versus 0.83 0.24 in controls, not significant),
p30 (0.41 0.08 in mutants, versus 0.53 0.11 in controls, not
significant), and p45 isoforms (0.11  0.01 in mutants, versus
0.12  0.01 in controls, not significant) remained unchanged.
Thus in the absence of ShcA, ErbB3 dysregulation precedes
abnormal expression of the p26 and p30 isoforms of Nrg-1.
Upon binding of Nrg-1, ErbB receptors generate signals inside
FIGURE 3.Absence of vascular phenotypewhen ShcA is deleted in vascu-
lar smooth muscle cells. A, Western blot analysis of ShcA in the indicated
tissues from 3-month-old smShcA and control mice (Ctrl). B, H&E staining
and electronmicroscopy analysis of aortas from smShcAmice and controls.
Scale bars 200mm (left panels) and 10m (right panels). C, vascular reactiv-
ity upon phenylephrine treatment (n  5 per group, 3-month-old mice). D,
quantitative analysis of atherosclerotic lesion size in aortas from cholesterol-
fed mice (n  6 per group). E, opened and Sudan IV-stained aortas from
cholesterol-fed mice that express or lack ShcA in vascular smooth muscle
cells. Scale bars 1 cm. Values are mean S.E.
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cells that diminish the inotropic response to adrenergic stimu-
lation, thereby mimicking an anti-adrenergic effect of musca-
rinic cholinergic receptor signaling (38). Consistent with a
down-regulation of ErbB3 signaling, we found an altered baro-
receptor reflex-induced decrease in the heart rate upon phen-
ylephrine treatment in the mutants (Fig. 4E). Taken together,
these data argue for a role of the ShcA-mediated ErbB3 signal-
ing in sarcomere function and integrity in the heart.
The cardiac homologue of nebulin, nebulette, is a sarcomeric
Z-disk protein involved in force generation via its interaction
with the actin and tropomyosintroponin complex and plays a
critical role in the formation of the thin filamentZ-line com-
FIGURE 4. Abnormal thin filamentZ-disk complex assembly in the absence of cardiac ShcA. A, abnormal myofibrillar ultrastructure as determined by
electronmicroscopy in conditionalmutant (smShcA) and control (Ctrl) mice at E14.5, E18.5, and 3-month-oldmice. Note the increase of the thickening of the
Z-disks (Z) (E18.5 and adults, top panels,white arrows) andundefinedM-band (M) structures (E18.5, adults, dark arrows) at embryonic stages.Mitochondrial (Mi)
swelling (adult, bottom panels) and abnormal T-tubules (T) (E14.5 and adult, middle panels, white arrows), which are no longer aligned with Z-disks and of
abnormalmorphology (bubbling, E14.5) are present. Scale bars: E14.5500nm; E18.51m; adults, top1m;middle500nm; bottom2m.B, Z-disk
width in the heart frommutant (smShcA) and (Ctrl) control embryos at E18.5 (n 4 per group). C, protein levels of the ErbB3 receptor and its ligand Nrg-1 at
E14.5 and E18.5, inmutant (smShcA) and (Ctrl) control hearts (n 4 per group).D, mRNA levels of the ErbB3 receptor in 3-month-oldmice (n 6 per group).
E, measurements of the heart rate upon phenylephrin treatment in 3-month-oldmutants (smShcA) and controls. Measurements were done in aminimumof
6mice per group. F, time course of themRNA levels of nebulette between E14.5 and 3months of age, inmutants (smShcA) and controls (n 4 per group).G,
protein levels of nebulette in 3-month-old mice. Values are mean S.E. with *, p	 0.05 and **, p	 0.01 compared with littermate controls.
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plex early during myofibrillogenesis (39). Mutations of nebu-
lette lead to increased Z-disk thickening, enlarged T-tubules
(40), dilated cardiomyopathy, and severe heart failure in mice
and humans (41). Because these events recapitulated most of
the phenotype observed in smShcAmice, we tested nebulette
signaling in the absence of cardiac ShcA.We found thatmRNA
levels of nebulette were down-regulated in E18.5 embryos, as
well as in adult hearts from smShcAmice comparedwith con-
trols (Fig. 4F). Similarly, protein levels of nebulette were down-
regulated in adult hearts from smShcA mice compared with
controls (Fig. 4G). Together, these data indicate that ShcA
mutation selectively affects nebulette expression in the Z-disk,
an event that can cause abnormal Z-disk assembly (40), and
might contribute to altered muscle force generation via the
interaction of nebulette with actin and the cardiac tropomyosin
troponin complex.
ShcA Mutation Differentially Affects Expression of Sarcom-
eric Proteins—Titin is a giant protein (over 3MDa) that extends
from the Z-disk to the M-band of the sarcomere (42) and has
been associated with human cardiac disease (43–46). In the
Z-disk, the sequence insertions Zis-1 and Zis-5 contain XSPXR
motif repeats that have been shown to be phosphorylated in
vitro by ERK1/2, an event that might require ShcA (30, 48). We
first measured the protein level of titin and found no significant
difference in embryonic or adult mutant mice (Fig. 5, A–C),
compared with controls. Using immunoprecipitation experi-
ments, we then measured phosphorylation of the recombinant
Zis-1 and Zis-5 motifs of titin in heart lysates. There was no
difference in the phosphorylation of these motifs between
mutants and controls (Fig. 5D). Thus, it is unlikely that altera-
tions of titin expression or posttranslational Z-disk modifica-
tion account for the observed cardiac phenotype in smShcA
mice.
ShcA Mutation Selectively Affects the Dystrophin Complex
Signaling Pathway—Because ShcA interacts with Cav-1, we
measured the expression of Cav-1 and Cav-3 and found a
higher protein level of Cav-1 (Fig. 6, A, B, andD) in the heart of
adult smShcA mice compared with controls, whereas Cav-3
protein expression was unaffected (Fig. 6, B and D). Consis-
tently, electronmicroscopy analysis showedmore caveolae for-
mation in adult hearts from smShcA mice compared with
controls (Fig. 6C). Cav-1 also interacts with -dystroglycan and
the DGC complex (49). Thus, we determined whether dystro-
phin signaling is altered in smShcAmice. We found a strong
redistribution of dystrophin labeling by immunohistochemis-
try analysis (Fig. 6A) and a substantial increase in dystrophin
protein expression in the heart from smShcA adult mice (Fig.
6, B andD) and embryos at E14.5 (Fig. 6E) compared with con-
trols. Furthermore, we found that the costameric protein
PMCA co-immunoprecipitated with ShcA and Cav-1 in heart
lysates from control mice, whereas in the heart from smShcA
mice, PMCA is absent from the complex (Fig. 7A). The same
results were observed in H9C2 rat cardiac myoblasts treated
with ShcA siRNA or control (Fig. 7B). There was no difference
in PMCA mRNA levels between mutant and control hearts
(PMCA-1, 0.85 0.07 versus 1; PMCA-2, 0.95 0.02 versus 1;
PMCA-4, 1.11  0.13 versus 1, not significant). Similarly,
immunofluorescent staining of Cav-1 and PMCA in isolated
cardiomyocytes from smShcA and controlmice (Fig. 7C) or in
H9C2 rat cardiac myoblasts treated with ShcA siRNA or con-
trols (Fig. 7D) showed co-localization of both proteins when
ShcA is expressed. We did not find any differences in the pro-
tein expression of the 71 integrin (Fig. 6, B and D) and its
downstream target paxilin (Fig. 6, B and D), which also signals
in costameres, suggesting that only the DGC is affected by the
absence of ShcA.Together, these data demonstrate that ShcA is
localized at costameres. They reveal an interaction between
ShcA, PMCA, and Cav-1, and indicate a role of ShcA in the
spatial organization of the costamere/Z-disk network, and car-
diomyocyte contraction.
DISCUSSION
In this study, we used a conditional knock-out of ShcA to
understand its function early during heart development and in
the progression of cardiovascular disease. We used Cre-loxP-
mediated recombination to introduce the ShcA deletion in car-
diomyocytes and found that the conditional mutant mice
develop a severe dilated cardiomyopathy, which is associated
with signs of myocardial infarction, such as T-wave inversions
and large necrotic areas, and occurrence of sudden death. The
numerous abnormalities seen in the sarcolemma demonstrate
for the first time that ShcA is required for sarcomere structure
and integrity during heart development. In particular, ShcA is
needed for a normal morphology of Z-disks and T-tubules. To
delete ShcA in the cardiovascular system early during develop-
ment we used the Cre transgene under the control of the sm22
promoter expressed from E8.5 (19). In mice, a single beating
FIGURE5.Titin signaling in theabsenceof cardiacShcA.A, SDS-agarosegel
electrophoresis and Coomassie Blue staining of titin in hearts from 3-month-
old mutants (smShcA) and controls. B, quantification of SDS-agarose gel
electrophoresis. C, SDS-agarose gel electrophoresis and Coomassie Blue
staining of titin in the heart frommutants (smShcA) and control embryos.D,
32P-phosphorylationof the recombinant titinZ-disk fragmentsZis-1 andZis-5
upon treatments with heart lysates from E18.5 and 3-month-old mutant and
control mice. Values are mean S.E.
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heart tube is formed by E8.0. At first, the contractions are irreg-
ular, but by E9.0 a regular heartbeat is established (50). In the
smShcAmice at E14.5, when atrial septation is not complete
and the heart has not yet achieved its definitive prenatal con-
figuration (32), ShcA was already efficiently deleted (Fig. 1A).
Previous reports suggested that the elimination of ShcA after
birth in cardiomyocytes using a Cre-loxP strategy with myosin
light chain-driven Cre recombinase (ShcA CKOmice), led to a
moderate cardiac phenotype (10). There was no evidence of
myofibrillar abnormalities, aberrant intercalated disks struc-
ture, or mitochondrial abnormalities in these mice (10). This
can be attributed to the late expression of themyosin light chain
transgene, starting at 2 weeks of age with efficient reduction of
ShcA expression at 12 weeks of age (10). Thus, the striking
difference between the onset of cardiomyopathy in smShcA
mice versus ShcACKOmice (10) ismost likely due to the earlier
reduction of ShcA in the smShcA mice. Alternatively, differ-
ences in the genetic background of the two lines of mice may
have a role, which might imply the existence of modifying loci
important for normal heart function in the absence of ShcA
signaling. Because the deletion occurs both in the heart and in
the vascular wall, we could not exclude a contribution of the
vascular system to the cardiac phenotype. However, we have
been unable to detect any vascular modification in the absence
of ShcA that may explain or contribute to the phenotype in
the heart. This also demonstrates that the expression of ShcA in
vascular smoothmuscle cells is not crucial for the development
of the vascular system. The only modification observed was a
FIGURE 6. Abnormal dystrophin signaling in the absence of cardiac ShcA. A, immunostaining of Caveolin-1 and dystrophin in 3-month-old conditional
mutant (smShcA) and control (Ctrl) hearts. Note the increase in the thickening of the dystrophin staining in the sarcolemma. Scale bars 100m. B, Western
blot of the indicated proteins in heart lysates from 3-month-old and, E, embryo (E14.5) conditional mutants (smShcA) and controls. C, electron microscopic
analysis of caveolae in3-month-old conditionalmutant (smShcA) andcontrol hearts.Scalebars1m.D,Westernblotdensitometric scanningof the relative
protein expressions of caveolin-1 (Cav-1), caveolin-3 (Cav-3), dystrophin (Dystro), 7 integrin (alpha7), and paxillin in the heart from 3-month-old mutants
(smShcA) and (Ctrl) controls (n 4 per group). E, Western blot of dystrophin in embryo (E14.5) conditionalmutants and controls. Values aremean S.E. with
*, p	 0.05 and **, p	 0.01.
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moderate increase in systolic blood pressure. However, the his-
tological and electron microscopy data obtained at E14.5 and
E18.5 strongly argues against pressure overload from systemic
hypertension as a major cause of the initial development of
heart failure. Hypertension development on an already dys-
functional heart may, however, accelerate heart failure result-
ing in premature death.
Nrg-1/ErbB signaling, which is enriched in T-tubules, is
indispensable in cardiac development (3, 4). Upon binding to
Nrg-1, ErbB regulates the expression of several sarcomeric pro-
teins, as well as cell-cell and cell-matrix interactions (37). Both,
the heart-specific knock-out of ErbB2 and its co-receptor
ErbB4 results in dilated cardiomyopathy (3, 4, 51). Further-
more, the Nrg-1/ErbB pathway has been described as a poten-
tial novel therapeutic target for heart failure (52, 53). Despite
the fact that ShcA interactswith ErbB receptors (54), we did not
find any changes in the expression of ErbB2 or ErbB4. Further-
more, in the case of the ErbB2 cardiomyocyte conditional
mutants, a normal myofibrillar ultrastructure was observed by
electronmicroscopy (3, 4), which was not the case in smShcA
mice. In contrast, we found that protein andmRNA levels of the
ErbB3 receptor, which also localize to the Z-disks (55), are
down-regulated in the adult heart. ErbB3 is expressed in prena-
tal cardiac myocytes and vascular endothelial cells (56) and has
been reported in adult mouse cardiac myocytes (55). However,
unlike ErbB2/4 receptors, which have now gained large recog-
nition, the role of the ErbB3 receptor inmaintaining heart func-
tion is not well known.Mice with a null mutation for ErbB3 die
in uterus at day E13.5 (57). Here we found that in the absence of
ShcA during heart development, ErbB3 protein expression is
severely altered at E14.5 (Fig. 4C) and precedes a decrease in
Nrg-1 protein expression at E18.5 (Fig. 4C). These data, along
with the abnormal baroreceptor reflex response observed in the
absence of ShcA, and which have been associated with ErbB
signaling, strongly suggests that the ErbB3 receptor is function-
ally deficient when ShcA is deleted before E14.5, and that integ-
rity of the ErbB3/ShcA pathway during embryogenesis is
required to maintain cardiac function in the adult.
7/1-Integrins are transmembrane proteins located at the
periphery of costameres that link the contractile apparatus to
the extracellular matrix, thereby playing an essential role in
sensing mechanical stress and in mechanotransduction (58).
The Z-disk protein complex that relay 7/1-integrin signals is
composed of proteins such as talin, paxillin, and vinculin. Talin
is a cytoskeletal protein that directly interacts with 7/1-in-
tegrins through its F1 and F3 domains (59). It was previously
demonstrated that ShcA binds to integrins (5, 6). However, we
did not find any modification in the protein levels of 7/1-
integrins in the absence of ShcA. Neither had we found any
modification in the protein expression of the talin downstream
signaling protein, paxillin in smShcA mice compared with
controls. Thus, in the absence of ShcA, the 7/1-integrin
pathway is not altered and ShcA does not cooperate with the
integrin/talin outside-in signal. In costameres, Cav-1 and -3 are
important components of the DGC. Cav-1-deficient mice have
demonstrated cardiac hypertrophy because of hyperactivation
of one of the ShcA target, Erk1/2 (47, 60). Because Cav-1 phys-
ically and functionally interacts with ShcA in caveolae (11), we
evaluated its expression in smShcA mice. The substantial
increase of Cav-1 protein levels in the smShcA mice heart
associated with an increase in the formation of caveolae dem-
onstrated that signaling through Cav-1 is altered in these mice.
In agreement, we found a profound redistribution of dystro-
phin labeling by immunofluorescence analysis associated with
an increase in the dystrophin protein levels in smShcA mice
hearts.
In the DGC, dystrophin binds to -syntrophin, which in
turns interacts with PMCA (14). Furthermore, a functional
interaction between ShcA and PMCAwas previously suggested
(17). Thus, PMCA could directly or indirectly interact with
ShcA and associate with Cav-1 and -syntrophin in the DGC.
Our data suggest that PMCA organizes such amacromolecular
complex in costameres, where ShcA by binding to both Cav-1
and PMCA links the contractile apparatus to the extracellular
matrix and thus plays a central role in cardiac function.
In conclusion, we demonstrate for the first time that ShcA
was localized to the DGC in the heart suggesting a role of ShcA
in protecting costameres/Z-disk axis structure and integrity,
FIGURE 7. ShcA and PMCA are associated in the heart dystrophin
glycoprotein complex. A, co-immunoprecipitation between ShcA, PMCA,
andCav-1 in heart lysates fromsmShcA and controlmice.B, co-immunopre-
cipitation between PMCA, P52 ShcA, and Cav-1 in H9C2 rat cardiacmyoblasts
treated with ShcA siRNA (ShcA/) or controls (ShcA/). C, immunofluores-
cent staining of Cav-1 and PMCA in isolated cardiomyocytes from 3-month-
old smShcA and control mice. D, immunostaining of Cav-1 and PMCA in
H9C2 rat cardiac myoblasts treated with ShcA siRNA (ShcA/) or controls
(ShcA/). Scale bars 10 m.
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and highlight ShcA as a new molecule for appropriate heart
formation during development.
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